

## Justin D. D'Aloia

Partner

New York | Securities Litigation


[jdaloia@pomlaw.com](mailto:jdaloia@pomlaw.com)

Justin D. D'Aloia is a leading class action attorney who specializes in securities fraud litigation. He has extensive experience litigating high-profile cases in federal and state courts across the United States against companies that operate in the financial services, life sciences, real estate, technology, and retail industries. His practice covers all aspects of dispute management, from pre-suit demand through trial or settlement.

Justin has secured a number of meaningful recoveries for investors. He recently negotiated a \$172.5 million settlement for investors in Danaher Corporation, which remains subject to court approval. Justin also recently finalized a \$10.5 million settlement with biotechnology company Immunity Bio for investors who said the company misled them about the likelihood of U.S. FDA approval of its bladder cancer drug.

Before joining Pomerantz, Justin was counsel at a large international law firm, where he focused on securities litigation and other complex shareholder class action litigation. He previously served as a law clerk to Judge Mark Falk of the United States District Court for the District of New Jersey.

Justin received his J.D. from Fordham University School of Law, where he was Editor-in-Chief of the *Fordham International Law Journal*.



### EDUCATION

- Fordham University School of Law
- Juris Doctor
- Rutgers University
- Bachelor of Science, Economics

### ADMISSIONS

- New York
- United States District Courts for the District of Colorado
- United States District Courts for the Southern and Eastern Districts of New York
- United States District Courts for the Northern District of Texas
- United States Courts of Appeals for the First, Second, Third, Fifth, and Tenth Circuits

## Publications

- “Pomerantz Secures Important Win in Case Against B. Riley Financial”, *The Pomerantz Monitor*, Vol 23, Issue 1, March/April 2026
- “Pomerantz Secures \$10.5 Million Settlement for ImmunityBio Investors”, *The Pomerantz Monitor*, Vol. 22, Issue 4, July/August 2025
- “Goldman Sachs Cert Redux,” *The Pomerantz Monitor*, Vol. 20, Issue 5, September/October 2023

## Accolades

- *Benchmark Litigation* “40 & Under” List (2024-2025)
- *Lawdragon* Leading Plaintiff Financial Lawyer (2019-2026)
- *Super Lawyers*® “Top-Rated” Securities Litigation Attorney” (2016-2026)
- *Martindale-Hubbell AV*® *Preeminent*™ *Peer-Rated Attorney* (2014-2025)
- *American Lawyer* Top Rated Litigator (2023)
- *Benchmark Litigation* Star (2021-2023)
- *Northeast Trailblazer* (2021)
- *Legal 500* Recommended Securities Litigator (2016, 2021)